Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.
Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.
SINTX Technologies (NASDAQ: SINT) will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close, and host a conference call and webcast at 4:30 p.m. ET to review quarterly performance.
The call will feature CEO and Chairman Eric Olson and CFO Kevin Trask. Investors can join via a live webcast on the company’s investor relations site or by telephone after advance registration. A replay will be available on the Events & Webcasts page.
SINTX Technologies (NASDAQ: SINT) has engaged Southern Metrics Consulting, led by CEO and SINTX director Chris Lyons, to establish and manage a new Strategic Opportunity Management Program aimed at identifying, evaluating, and pursuing strategic opportunities to support long-term growth and enhance stockholder value.
Working with SINTX’s executive team and Board, Southern Metrics will help assess potential commercial partnerships, licensing deals, strategic investments, joint ventures, acquisitions, divestitures, and other corporate development initiatives. SINTX views this as a key step in its evolution from an advanced biomaterials developer toward a commercial-stage medical technology company leveraging its silicon nitride platforms and FDA-cleared SINAPTIC Foot & Ankle Implant System.
SINTX Technologies (NASDAQ:SINT) received more than $3.2 million in aggregate purchase orders from multiple contract manufacturing customers for advanced ceramic components. The orders come from several existing relationships, with production and shipments expected to start in the second half of 2026 and extend into 2027.
SINTX Technologies (NASDAQ:SINT) entered securities purchase agreements for a $4.5 million private placement priced at-the-market under Nasdaq rules, issuing 1,882,845 common shares plus Class A and Class B warrants.
Together with a recent $0.5 million ATM sale, SINTX raised about $5.0 million for working capital, commercialization, business development and other strategic uses.
SINTX Technologies (NASDAQ:SINT) will present at the LD Micro Invitational XVI Conference in Los Angeles at the Luxe Sunset Blvd Hotel.
Management plans to discuss commercialization progress, product development, and manufacturing initiatives for its silicon nitride biomaterials platform and will hold one-on-one investor meetings. A live webcast will be available.
SINTX Technologies (NASDAQ: SINT) reported clinical, operational, and leadership milestones positioning the company for commercialization and revenue growth in 2026. Key items include first human implant of the FDA 510(k)-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, a ~$10 million capital raise, and the appointment of Ryan Elmore as President.
The company completed strategic divestitures, acquired SiNAPTIC Surgical, expanded its patent estate into antipathogenic textiles, executed a supply agreement with Evonik, and initiated preclinical studies for sutures, meshes, and wound care.
SINTX Technologies (NASDAQ: SINT) announced a clinical and commercial milestone: the first-in-human surgery using its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System. The device received U.S. FDA 510(k) clearance in October 2025 and was implanted on March 13, 2026, marking SINTX's entry into foot and ankle reconstruction.
The system uses silicon nitride biomaterial, highlighted for osteoconductivity, bacteriostatic surface characteristics, hydrophilicity, and compatibility with X-ray, CT, and MRI imaging. SINTX expects the SINAPTIC system to support a U.S. commercial launch and broader adoption across orthopedic applications.
SINTX Technologies (NASDAQ: SINT) appointed Ryan Elmore as President, effective March 16, 2026, to lead commercialization and channel expansion of silicon nitride biomaterial platforms including SiNERGY™ SiN/PEEK and antipathogenic fibrous materials. The role focuses on scaling revenue via licensing, partnerships, and new product forms (filament, rod, sheet).
The company signaled a strategic shift from product-focused manufacturing toward a broader biomaterials platform targeting implantable and non-implantable medical applications.
SINTX Technologies (NASDAQ: SINT) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on February 4–5, 2026, with its presentation on Wednesday, February 4, 2026 at 12:00 p.m. ET.
The webcast will be available via the company’s investor site. Management will provide updates on operational progress, strategic priorities, its silicon nitride biomaterial platform, recent regulatory milestones, and opportunities in orthopedic, spine, and patient-specific applications.
SINTX Technologies (NASDAQ: SINT) will present at Sidoti & Company’s Year End Virtual Investor Conference held December 10–11, 2025. Management's presentation is scheduled for Wednesday, December 10, 2025 at 3:15 P.M. ET. A live webcast is available and one-on-one meetings can be scheduled by emailing Sintx@kcsa.com. To join the company's email distribution list, email Sintx@kcsa.com with SINT in the subject line.